Elan Corporation has announced that results from phase three clinical trials on its transdermal nicotine patch mean a new drug application (NDA) for the product will not be filed.

The patch which contains a combination of nicotine and mecamylamine failed to show "sufficient statistical difference against a nicotine alone patch to support an NDA filing," the company said.